Stock comparison

JNJvsRPRX

Johnson & JohnsonvsRoyalty Pharma PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

JNJ

Johnson & Johnson

$230.65

+9.01%

Pharmaceuticals$585.7BNYSE

RPRX

Royalty Pharma PLC

$49.64

+29.34%

Pharmaceuticals$27.1BNASDAQ

60-day price, rebased to 100

JNJ +1.29% · RPRX +19.10%

Round-by-round

JNJ 3·RPRX 3

EdgeJNJ

Valuation upside

-37.60% vs -57.50% to DCF fair value

EdgeJNJ

Balance-sheet strength

Altman Z 5.08 vs 2.25

EdgeRPRX

Fundamental quality

Piotroski 4.00 vs 5.00 (of 9)

EdgeRPRX

Growth + margins

Rule-of-40 26.60 vs 109.80

EdgeRPRX

60-day momentum

+1.29% vs +19.10% price return

EdgeJNJ

Market-cap liquidity

$585.7B vs $27.1B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onJNJorRPRX

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.